DOUBLE-EXPRESSOR LYMPHOMA
Clinical trials for DOUBLE-EXPRESSOR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DOUBLE-EXPRESSOR LYMPHOMA trials appear
Sign up with your email to follow new studies for DOUBLE-EXPRESSOR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Pronged attack tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new two-step treatment for people with a high-risk type of aggressive lymphoma who haven't had treatment before. First, patients receive a targeted drug combination designed to seek out and kill cancer cells. This is followed by a standard, but intensive, …
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug targets 'Undruggable' cancer driver in Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage trial is testing a new drug called pidnarulex (CX-5461) in adults with aggressive, hard-to-treat B-cell lymphomas that have a specific genetic feature called MYC aberration. The main goals are to find the safest and most effective dose and to see if the drug can …
Matched conditions: DOUBLE-EXPRESSOR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC